Management Team

Chief Executive Officer: Brian Culley, MBA
Brian Culley previously served as Mast Therapeutics, Inc.’s (“Mast”) Chief Executive Officer since February 2010 and member of its Board of Directors since December 2011, until Mast’s merger with Savara, Inc. (SVRA) in April 2017. Mr. Culley served from January 2007 to February 2010 as Mast’s Chief Business Officer and Senior Vice President, from February 2006 to January 2007 as Mast’s Senior Vice President, Business Development, and from December 2004 to February 2006 as Mast’s Vice President, Business Development. From 2002 until 2004, Mr. Culley was Director of Business Development and Marketing for Immusol, Inc. From 1999 until 2000, he worked at the University of California, San Diego (UCSD) department of technology transfer & intellectual property services and from 1996 to 1999 he conducted drug development research for Neurocrine Biosciences, Inc. Mr. Culley has 25 years of business and scientific experience in the life science industry. He received a B.S. in biology from Boston College, a masters in biochemistry and molecular biology from the University of California, Santa Barbara, and an M.B.A. from The Johnson School of Business at Cornell University.

Chief Scientific Officer: Dana Wolf, MD, PhD
Dana Wolf is the Chief Scientific Officer of Artemis Therapeutics. She is a Professor of Virology and Infectious Diseases at the Hebrew University, Jerusalem, and the Director of the Clinical Virology Unit at the Hadassah Medical Center, Jerusalem, Israel. She received her M.D. degree at the Hebrew University Hadassah Medical School, and completed her Internal Medicine residency and her fellowship in Infectious Diseases at the Hadassah Medical Center. She pursued a postdoctoral fellowship in Virology at the University of California San Diego and later spent a year as a visiting scientist at Stanford University. Her studies focus on human cytomegalovirus (HCMV) transmission and pathogenesis, employing a unique ex vivo human placental model to characterize the mode of maternal-to-fetal viral transmission and the impact of placental innate immune responses and new antiviral approaches on the outcome of congenital infection. Dr. Wolf’s lab further focuses on the discovery and evaluation of novel antiviral drugs and drug targets, the mechanism of HCMV antiviral drug resistance and its clinical impact, and the epidemiology and early detection of congenital HCMV infection. Dr. Wolf is a member of several national and international advisory committees and boards, including the Advisory Committee on Immunization Practices and Infectious Diseases in Israel, and the European Society for Virology Executive Board. She is a member of the Lautenberg Center for General and Tumor Immunology, and has been an active partner in EU Marie Curie and Infect-ERA Consortiums.

Chief Financial Officer: Chanan Morris
Chanan Morris has been the Chief Financial Officer of Artemis Therapeutics since its inception in April 2016. He previously served as the Chief Financial Officer of New York Global Innovations Inc and was instrumental in the consummation of the reverse merger transaction between New York Global Innovations and Artemis.. Mr. Morris has also served as the Chief Financial Officer of Galmed, a biomedical Company and together with the CEO completed an IPO on the Nasdaq stock exchange. Prior to that Mr. Morris also served as the CFO of Surpass Medical Ltd during its acquisition by Stryker Corporation (NYSE:SYK) which was successfully completed in 2012. Mr. Morris is currently a director at the Infinity Group and serves as a board member of several of its Companies in the United States and China as well as serving as Vice President of Finance & Operations for some of the Groups’ companies including Mango DSP Ltd and its subsidiaries. Mr. Morris has held numerous senior management positions in finance, operations and as acting CEO and has been successful in the completion of merger and acquisitions, financing and an Initial Public Offering. He received his B.Sc. in Accounting from Northeastern University.